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Objectives: Influenza, an acute viral infection causing annual epidemics, has 
a major impact on healthcare systems and society, but can be effectively pre-
vented using vaccination. The World Health Organization currently recommends 
that influenza vaccines should include at least two virus A and one virus B lin-
eages (trivalent vaccines; TIVs). A new quadrivalent vaccine, offering broader 
protection against influenza by including an additional virus B strain, received 
regulatory approval and is now recommended by several immunization com-
mittees (Advisory Committee on Immunization Practices (USA), Joint Committee 
on Vaccination and Immunisation (UK)). The present study was undertaken to 
estimate the cost-effectiveness of replacing TIVs with the quadrivalent influenza 
vaccine in Spain. MethOds: A static, lifetime, multi-cohort model with a one-
year cycle time was developed to assess the costs and health outcomes associated 
with trivalent vs. quadrivalent vaccines. The model followed the lifetime of a 
cohort vaccinated each year according to local health authority recommendations. 
Information on circulating influenza virus strains, obtained from the National 
Epidemiology Centre, allowed the determination of whether the B strain included 
in TIVs matched the circulating one. The cost-effectiveness analysis was con-
ducted from a societal perspective. The costs and outcomes were discounted at 3% 
and the robustness of the results was tested using one-way and probabilistic sensi-
tivity analyses. Results: Compared with TIVs, the quadrivalent influenza vaccine 
reduced the number of influenza cases, as well as influenza-related complications 
and deaths. The incremental cost-effectiveness ratio (ICER) was 8,748 € /QALY. 
One-way sensitivity analysis showed virus A circulation and mismatch with the 
B lineage included in TIVs as main drivers for ICER. Using probabilistic sensitivity 
analysis, ICER was below 30,000 € /QALY in 96% of the simulations. cOnclusiOns: 
Replacing TIVs with quadrivalent influenza vaccine for national immunization 
programs in Spain could improve prevention by avoiding virus B mismatch and 
provide a cost-effective healthcare intervention.
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Objectives: Chronic Hepatitis C (CHC) is an infectious disease associated with 
significant morbidity and mortality. Early access to treatment may mitigate the rise 
in CHC-related morbidity and mortality and prevent onward transmission. We have 
examined the cost-effectiveness of providing broad access to treatment compared 
with limiting treatment to patients with advanced fibrosis. MethOds: A Markov 
model with a lifetime horizon was constructed to assess the relative costs and 
outcomes of treating a population of patients with CHC regardless of fibrosis stage 
compared with restricting treatment until patients developed F3 or F4 (METAVIR sys-
tem) fibrosis. Cycle length was 6 months, and costs and benefits were discounted at 
an annual rate of 3.5%. Published literature provided cost, natural history, and utility 
data. Patients entered the model at fibrosis stages F0-F4 (F0= no fibrosis; F4= com-
pensated cirrhosis) reflective of the current distribution of fibrosis scores in the UK. 
In each cycle, patients remained in their current health state, achieved a sustained 
virologic response (equivalent to a cure), experienced disease progression or died. 
Advanced liver disease states (decompensated cirrhosis, hepatocellular carcinoma, 
and transplantation) were associated with excess mortality. Cost-effectiveness was 
assessed using the incremental cost-effectiveness ratio (ICER), expressed as cost per 
quality-adjusted life year (QALY). Results: Preliminary results indicate that treating 
all patients compared with the restricted treatment strategy is associated with 
incremental costs of £4,098 and incremental QALYs of 1.44 per patient, resulting 
in an ICER of approximately £2,855. cOnclusiOns: Treating all patients is cost-
effective compared with restricting treatment to patients with advanced fibrosis 
only. The latter strategy is unlikely to mitigate the future burden of HCV-related 
healthcare or significantly reduce onward transmission. Treating all patients aligns 
closely with the NHS Five Year Forward View strategy which strongly emphasises 
prevention and public health, and would facilitate strategies to raise awareness 
and treatment of HCV.
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Objectives: One significant innovation of combination antiretroviral ther-
apy (cART) has been the introduction of a once-daily fixed-dose combination 
to either maintain or increase treatment adherence. DTG/ABC/3TC is a highly 
efficacious and well-tolerated once-daily regimen for HIV-infected patients. The 
objective of the study was to assess the cost-utility (C/U) of treatment initia-
tion with DTG/ABC/3TC single tablet regimen (STR) in ART-naïve HIV infected 
patients. MethOds: A microsimulation model was developed to compare, from 
the Spanish Health System perspective, the C/U of treatment inititation with 
DTG/ABC/3TC vs. the treatment initiation with any of the following regimens: 
Emtricitabine/Tenofovir/Efavirenz (FTC/TDF/EFV), and Darunavir/r (DRV/r) or 
Raltegravir (RAL) with Emtricitabine/Tenofovir (FTC/TDF) or Abacavir/Lamivudine 
(ABC/3TC) over a lifetime horizon. One million subjects were simulated using data 
from the trial were mapped to quality of life data from the literature to estimate the 
effectiveness of each vaccine. The time horizon was one year’s influenza season for 
costs and a lifetime for quality-adjusted life years (QALYs). Results: The average 
per-participant direct medical costs (including vaccine cost) and societal costs were 
$47 and $60 lower in the HD arm. Hospitalizations represented over 91% of the total 
cost and were less frequent in the HD arm (7.7% of HD participants reported ≥ 1 
hospitalization versus 8.4% in SD arm) and average length of stay (LOS) across all 
participants was shorter in the HD arm (0.49 days vs 0.56 days). HD was associated 
with 0.0004 more QALYs per participant and, due to cost savings, dominated SD in the 
CUA. cOnclusiOns: Despite the higher price of HD vs. SD, the total direct medical 
and societal costs were lower per HD vaccinee. This was driven by a reduction in the 
number of hospitalizations and in the LOS for those hospitalized. HD dominated 
SD in the CUA.
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Objectives: Infection with varicella-zoster virus (VZV) causes two distinct vaccine-
preventable diseases: varicella and herpes zoster (HZ). Universal childhood varicella 
vaccination is recommended in Germany since 2004. However, country-wide vac-
cination against HZ has not been introduced yet. The objective of this study was to 
estimate the cost-effectiveness of different VZV vaccination strategies in Germany 
from a societal perspective: (i) additional introduction of routine HZ vaccination in 
the elderly, (ii) discontinuation of universal varicella vaccination, or (iii) a combina-
tion of both previously mentioned options. MethOds: The health economic analy-
sis was based on an age-structured model of VZV transmission and vaccination in 
Germany. The time horizon of the dynamic model was 100 years. Treatment costs of 
varicella and HZ were estimated from health insurance claims data. A 3% discount 
rate was used for future costs and health effects. All vaccination strategies were 
evaluated assuming the existence or non-existence of exogenous boosting. When 
assuming exogenous boosting, universal childhood varicella vaccination might cause 
an increased HZ incidence in the elderly. Results: Compared to current universal 
two-dose childhood varicella vaccination, the incremental cost-effectiveness ratio of 
additional HZ vaccination (base-case: vaccination at 60 years of age and waning of 
vaccine-induced immunity) was EUR 50,978 and EUR 47,720 per quality-adjusted life 
year (QALY) when assuming the existence and non-existence of exogenous boost-
ing, respectively. Discontinuation of universal varicella vaccination led, irrespective 
of additional HZ vaccination, to both cost-savings and QALY gains when considering 
exogenous boosting. When exogenous boosting was discarded, cost-savings came 
along with QALY losses. cOnclusiOns: The economic benefit of universal child-
hood varicella vaccination depends strongly on the existence of exogenous boosting. 
Further research is needed to measure the extent of exogenous boosting and its 
impact in health economic evaluations. Additional HZ vaccination can be consid-
ered as a marginally cost-effective intervention when considering a cost per QALY 
threshold of EUR 50,000.
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Objectives: Chronic hepatitis C virus (HCV) is a considerable public health concern 
due to its significant impact on morbidity, mortality and healthcare costs in the 
Netherlands. Clinical studies of ombitasvir/paritaprevir/ritonavir and dasabuvir 
(OBV/PTV/r/DSV) with and without ribavirin have demonstrated high sustained viral 
response (SVR) rates for treatment of genotype 1 (GT1) and 4 (GT4) HCV patients. 
This study aims to evaluate the health economic value of OBV/PTV/r/DSV versus 
sofosbuvir in combination with pegylated interferon and ribavirin (SOF+PR) using 
a cost-utility analysis for HCV treatment-naïve patients with GT1 or GT4 in the 
Netherlands. MethOds: A Markov model with a lifetime horizon was developed 
based on previous published disease models and adapted to Dutch societal per-
spective. SVR rates, adverse events, regimen duration were gathered from pub-
lished phase 3 trials. Transition probabilities, health state utilities resource use and 
costs were derived from literature, publically available sources and expert opinion. 
Baseline characteristics (e.g., age, fibrosis distribution) were based on the OBV/
PTV/r/DSV trials. Total costs and QALYs were calculated per treatment option along 
with respective incremental cost-effectiveness ratios. Results: In treatment-naïve 
GT1 patients with or without cirrhosis, OBV/PTV/r/DSV dominates SOF+PR at higher 
incremental QALYs (range: 0.09 to 0.51) and lower incremental costs (range: € -2,992 
to € -13,077). For treatment-naïve GT4 patients, OBV/PTV/r/DSV dominates SOF+PR at 
higher incremental QALYs (0.04) and lower incremental costs (€ -7,862). The results 
were robust to parameter uncertainty. Probabilistic sensitivity analysis shows OBV/
PTV/r/DSV is cost-effective vs SOF+PR in 72% to 80% of simulations for GT1; 88% for 
GT4 patients respectively. cOnclusiOns: At higher incremental health benefits 
and lower incremental costs, OBV/PTV/r/DSV dominates SOF+PR in treatment-naive 
GT1 and GT4 HCV patients. OBV/PTV/r/DSV improves the morbidity and economic 
impact of treating GT1 and GT4 HCV patients in the Netherlands.
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